Filing identity and reporting period
The supplied filing is for MEI Pharma, Inc. (Nasdaq: MEIP), not Lite Strategy, Inc. It is a Form 10-Q for the quarter ended December 31, 2021, the second quarter of MEI Pharma’s fiscal 2022; the filing does not match the requested company or 2020 Q2 period. Financial statements are unaudited. Amounts below are in U.S. dollars unless stated otherwise.
Business context and financial results
MEI Pharma is a clinical-stage oncology company developing zandelisib, voruciclib and ME-344. Revenue is primarily from license and collaboration arrangements, rather than product sales.
| Metric | Three months ended Dec. 31, 2021 | Six months ended Dec. 31, 2021 | Comparable 2020 period |
|---|---|---|---|
| Revenue | $18.2 million | $31.6 million | $9.2 million and $13.0 million, respectively |
| Operating expenses | $29.5 million | $57.3 million | $28.4 million and $47.8 million, respectively |
| Operating loss | $11.2 million | $25.7 million | $19.2 million and $34.8 million, respectively |
| Net loss | $5.8 million | $17.6 million | $11.5 million and $13.5 million, respectively |
| Operating cash used | $16.3 million for six months | $5.1 million for six months |
Revenue increased primarily as KKC-related research and development performance obligations were satisfied. The company reported no cost of revenue in the 2021 periods. Operating loss as a share of revenue was approximately 62% for the quarter and 81% for the six-month period. Net loss benefited from non-cash gains on remeasurement of warrant liabilities: $5.5 million for the quarter and $8.0 million for six months. These gains reduced the reported net loss and do not represent operating cash inflows.
Liquidity, capital and balance sheet
At December 31, 2021, cash and cash equivalents plus short-term U.S. government investments totaled $185.8 million, versus $153.4 million at June 30, 2021. Current assets were $200.7 million and current liabilities $30.5 million. Total liabilities were $132.2 million, including $14.3 million of warrant liability and $7.8 million of operating lease liabilities. The filing reports no conventional borrowings. Accumulated deficit was $345.5 million.
Cash from financing activities was $48.7 million for the six months, mainly net proceeds from a December 2021 registered offering of 20.125 million shares at $2.60 per share. The offering produced $48.7 million net proceeds after $3.7 million of costs. Investing activities used $28.4 million, primarily reflecting net purchases of short-term investments. The company stated that available resources were expected to fund operations for at least 12 months from issuance of the filing.
Changes versus the prior comparable period
- Six-month revenue rose to $31.6 million from $13.0 million, while operating loss narrowed to $25.7 million from $34.8 million.
- Six-month net loss widened to $17.6 million from $13.5 million, despite the narrower operating loss, as the prior-year period included a larger $20.3 million non-cash warrant fair-value gain versus $8.0 million in 2021.
- Six-month research and development expense increased to $41.5 million from $35.2 million, reflecting higher drug-manufacturing, clinical-program and personnel costs. General and administrative expense increased to $15.8 million from $11.6 million, including greater commercial-launch preparation costs.
- Operating cash use increased to $16.3 million from $5.1 million, reflecting increased development activity and working-capital changes.
- Shares outstanding increased to 132.9 million at December 31 from 112.6 million at June 30, primarily due to the equity offering.
Outlook, developments and risks
- Management expects operating losses and negative operating cash flows for the foreseeable future, with research and development spending expected to rise. It anticipates needing additional capital at some point; future financing availability is not assured.
- Management cited TIDAL Phase 2 data in follicular lymphoma: an independent-review response rate of 70.3% and complete response rate of 35.2% in the primary efficacy population of 91 patients. Duration-of-response data were not yet mature. The filing describes COASTAL, a Phase 3 zandelisib study, as intended to support full marketing applications and potentially serve as a confirmatory study.
- During the six months, two KKC milestones totaling $20 million were earned and recorded as deferred revenue, to be recognized as performance obligations are met. KKC may pay up to approximately $582.5 million in additional development, regulatory and commercial milestones, plus ex-U.S. royalties; these potential amounts are not assured.
- Management planned a voruciclib–venetoclax Phase 1b study in AML by mid-2022 and a ME-344/bevacizumab Phase 1b study in relapsed colorectal cancer in mid-2022. These are forward-looking plans, not reported achievements.
- COVID-19 had delayed or slowed enrollment in some trials and could further affect enrollment, study timelines, data integrity, manufacturing and regulatory review. Other material risks include clinical-trial outcomes, regulatory approval, partner performance, competition, and the need for further funding.
- The Helsinn license agreement was terminated in November 2021. The company reported no legal proceedings and no material changes to the risk factors in its prior annual report. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Key facts for investors to verify
- Confirm the issuer and period: this is MEI Pharma’s quarter ended December 31, 2021, not Lite Strategy’s 2020 Q2 filing.
- Review subsequent TIDAL and COASTAL trial results, FDA interactions and development timelines; the filing’s efficacy figures are interim and do not establish approval or commercial success.
- Assess the cash runway against clinical spending plans, future financing needs and potential dilution from equity issuance, options and warrants.
- Distinguish recurring operating performance and cash burn from non-cash warrant remeasurement gains and license-related revenue recognized over time.
- Check the status and terms of KKC collaboration obligations, milestone conditions, deferred revenue and any future capital or partnership transactions.